A Rare Cause of Severe Hypoglycaemia



How to Cite

Etchie, L., Fernando, D. ., Muraleedharan , V. ., & Poduval , A. . (2021). A Rare Cause of Severe Hypoglycaemia. The Physician, 6(3), 1-5. https://doi.org/10.38192/


A 67-year old woman presented with an unwitnessed fall and decreased oral intake. She had a learning disability, hypertension, epilepsy, asthma, chronic iron deficiency anaemia, mild lymphopenia, osteoporosis and treated uterine cancer. After clinical review, she was treated for Hospital-acquired pneumonia (following a recent hospital admission) with possible aspiration. She was noted to have hyponatraemia secondary to dehydration. She was commenced on intravenous Levofloxacin and Metronidazole along with supportive care, based on antibiotic guidance due to her known allergy to penicillin.
On day 3 of admission, she was found unresponsive with a capillary blood glucose of 0.6 mmol/L, which improved with 10% glucose infusion. The low blood glucose was attributed to poor oral intake. However, her serial blood sugar results demonstrated persistent hypoglycaemia for 72h  needing further intravenous glucose infusions. A medication review was undertaken and Levofloxacin was discontinued. After 24hrs of discontinuation, the hypoglycaemic episode resolved. A short synacthen test showed a normal cortisol response. There were no further episodes of hypoglycaemia.


As her persistent hypoglycaemia resolved on discontinuation of Levofloxacin, a diagnosis of fluoroquinolone induced hypoglycaemia was reported to MHRA. Fluoroquinolones are thought to induce hypoglycaemia by increasing the insulin release via blockade of adenosine triphosphate-sensitive K+channels in the β cells of the pancreas. This effect may not be clinically evident in all patients because of physiologic mechanisms that regulate blood glucose levels. 
Health professionals should be aware of the potential risk of severe hypoglycaemia with the use of Fluoroquinolones which are a first or second-line treatment for common infective processes. Fluoroquinolones should be stopped immediately and switch to a non-Fluoroquinolones antibiotic if possible. In elderly patients with compromised oral intake or in those with other comorbidities, regular blood glucose monitoring should be carried out to avoid life-threatening hypoglycaemic episodes.




Whipple AO. Islet cell tumours of the pancreas. Canadian Medical Association Journal 1952 66 334–342.)

Non-Diabetic Hypoglycaemia. Best Practice, British Medical journal.

Towler DA, Havlin CE, Craft S, Cryer P 1993 Mechanism of awareness of hypoglycaemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42:1791–1798.

Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P & Gerich J. Hierarchy of glycaemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. American Journal of Physiology 1991 260 E67–E74.

reference Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER & Service FJ. Evaluation and management of adult hypoglycaemic disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2009 94 709–728. (doi:10.1210/jc.2008-1410.

MarksV, Teale JD1999 Drug-induced hypoglycaemia. Endocrinol Metab Clin North Am 28:555–577.

Mays H. Vue, PharmD and Stephen M. Setter, PharmD, CDE, CGP. Diabetes Spectrum 2011 Aug; 24(3): 171-177.

Impact of Hypoglycaemia on Morbidity and Mortality. Annals of Long-term Care. September 23, 2015.www.managedhealthcareconnect.com.

Amit Akirov, Alan Grossman, Tzipora Schochats, Ikin Shimon. Mortality Among Hospitalized Patients with Hypoglycaemia: Insulin Related & Non-Insulin Related. The Journal of Clinical Endocrinology & Metabolism volume 102, Issue 2, 1 Feb.2017. Pages 416-424.

Markolf Hanefold, Eva Duetting, Peter Bramlage. Cardiac Implications of Hypoglycaemia in Patients with Diabetes -A Systematic Review. Cardiovascular Diabetology. 12, Article number 135 (2013).


Sherrie L. Aspinall, Chester B. Good, Rong Jiang, Madeline McCarren, Diane Dong, Francesca E. Cunningham. Severe Dysglycaemia with the Fluoroquinolones: A Class Effect? Clinical Infectious Diseases, Volume49, Issue 3, 1 August 2009.

Maeda N, Tamagawa T, Niki I, Miura H, Ozawa K, Watanabe G, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996;117(2):372–6.

Saraya A, Yokokura M, Gonoi T, Seino S. Effects of Fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol. 2004 Aug 16;497 (1):111-7 PMID: 15321742.

FDA: Tequin Was Withdrawn From U.S. Market “For Reasons Of Safety or Effectiveness” Drug Injury Watch. www.drug-injury.com. September 10, 2008.

Seltzer HS. Drug-induced hypoglycaemia. A review based on 473 cases. Diabetes 1972 21 955–966. (doi:10.2337/diab.21.9.955) 76 Seltzer HS. Drug-induced hypoglycaemia. A review of 1418 cases. Endocrinology and Metabolism Clinics of North America 1989 18 163–183. (doi:10.2337/diab.21.9.955) 77 Fischer KF, Lees JA & Newman JH. Hypoglycemia in hospitalized patients. Causes and outcomes. New England Journal of Medicine 1986 315 1245–1250. (doi:10.1056/NEJM198611133152002)).

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Array